Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.39 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.35 |
| ▸ | S100A4 | P26447 | 2/20 | 0.35 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20694863 | 1.00 | GSK3B (0.39) | GSK3BEP300KAT2BS100A4RAD51 | |
| SCHEMBL18058838 | 0.90 | MEN1 (0.36) | EP300KAT2BS100A4RAD51 | |
| SCHEMBL18058759 | 0.89 | S100A4 (0.34) | EP300KAT2BS100A4RAD51 | |
| SCHEMBL20102793 | 0.88 | GSK3B (0.35) | GSK3B | |
| SCHEMBL15731795 | 0.86 | PIK3R1 (0.39) | EP300KAT2BRAD51 | |
| SCHEMBL18410353 | 0.86 | GSK3B (0.34) | GSK3B | |
| SCHEMBL1919863 | 0.84 | AKR1C3 (0.44) | EP300KAT2BRAD51 | |
| SCHEMBL17576245 | 0.84 | AKR1C3 (0.44) | — | |
| SCHEMBL29483984 | 0.84 | RAD51 (0.51) | RAD51 | |
| SCHEMBL6330031 | 0.84 | KMT2A (0.49) | RAD51 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590133-B2 | Dimer impurities of Apixaban and method to remove them | F.I.S.-FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2020-03-17 | — | — | US | disclosed |
| US-10385049-B2 | Dimer impurities of apixaban and method to remove them | F.I.S.—Fabbrica Italiana Sintetici S.p.A. (IT) | 2019-08-20 | — | — | US | disclosed |
| EP-3280714-B1 | DIMER IMPURITIES OF APIXABAN AND METHOD TO REMOVE THEM | FIS FABBRICA ITALIANA SINTETICI SPA (IT) | 2019-02-06 | — | — | EP | disclosed |
| US-20180118737-A1 | DIMER IMPURITIES OF APIXABAN AND METHOD TO REMOVE THEM | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2018-05-03 | — | — | US | disclosed |
| US-20180118737-A1 | DIMER IMPURITIES OF APIXABAN AND METHOD TO REMOVE THEM | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2018-05-03 | — | — | US | disclosed |
| WO-2017013079-A1 | DIMER IMPURITIES OF APIXABAN AND METHOD TO REMOVE THEM | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2017-01-26 | — | — | WO | disclosed |
| EP-3064497-A1 | DIMER IMPURITIES OF APIXABAN AND METHOD TO REMOVE THEM | F.I.S.- Fabbrica Italiana Sintetici S.p.A. (IT) | 2016-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590133-B2 | Dimer impurities of Apixaban and method to remove them | F2, FGB, F8 | GSK3B 893/4885EP300 4738/4885KAT2B 3782/4885 |
| US-10385049-B2 | Dimer impurities of apixaban and method to remove them | F2, FGB, F8 | GSK3B 893/4885EP300 4738/4885KAT2B 3782/4885 |
| US-20180118737-A1 | DIMER IMPURITIES OF APIXABAN AND METHOD TO REMOVE THEM | F2, FGB, F8 | GSK3B 893/4885EP300 4738/4885KAT2B 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.